JP2008503498A - 癌の診断及び免疫療法における腫瘍関連抗原プロファイル - Google Patents

癌の診断及び免疫療法における腫瘍関連抗原プロファイル Download PDF

Info

Publication number
JP2008503498A
JP2008503498A JP2007516827A JP2007516827A JP2008503498A JP 2008503498 A JP2008503498 A JP 2008503498A JP 2007516827 A JP2007516827 A JP 2007516827A JP 2007516827 A JP2007516827 A JP 2007516827A JP 2008503498 A JP2008503498 A JP 2008503498A
Authority
JP
Japan
Prior art keywords
tumor
antigen
cancer
protein
ssx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007516827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008503498A5 (https=
Inventor
チャン，シウ−シェン
ジェイ．エル． シマード，ジョン
Original Assignee
マンカインド コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35478743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008503498(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by マンカインド コーポレイション filed Critical マンカインド コーポレイション
Publication of JP2008503498A publication Critical patent/JP2008503498A/ja
Publication of JP2008503498A5 publication Critical patent/JP2008503498A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007516827A 2004-06-17 2005-06-17 癌の診断及び免疫療法における腫瘍関連抗原プロファイル Pending JP2008503498A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58096904P 2004-06-17 2004-06-17
PCT/US2005/021836 WO2006002114A2 (en) 2004-06-17 2005-06-17 Tumor-associated antigen profiles in cancer diagnostics and immunotherapy

Publications (2)

Publication Number Publication Date
JP2008503498A true JP2008503498A (ja) 2008-02-07
JP2008503498A5 JP2008503498A5 (https=) 2008-08-07

Family

ID=35478743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007516827A Pending JP2008503498A (ja) 2004-06-17 2005-06-17 癌の診断及び免疫療法における腫瘍関連抗原プロファイル

Country Status (10)

Country Link
EP (1) EP1782070B1 (https=)
JP (1) JP2008503498A (https=)
AT (1) ATE480776T1 (https=)
AU (1) AU2005258014B2 (https=)
CA (1) CA2571070A1 (https=)
DE (1) DE602005023488D1 (https=)
DK (1) DK1782070T3 (https=)
ES (1) ES2351995T3 (https=)
MX (1) MXPA06014771A (https=)
WO (1) WO2006002114A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512415A (ja) * 2008-02-20 2011-04-21 アリゾナ バイオメディカル リサーチ コミッション 癌の治療および予防のための治療用ペプチドの使用
JP2012512389A (ja) * 2008-12-15 2012-05-31 オックスフォード バイオメディカ （ユーケー） リミテッド 方法
JP2012522217A (ja) * 2009-03-24 2012-09-20 バイオセプト インコーポレイティッド 細胞の捕捉および解析のデバイスおよび方法
US9585938B2 (en) 2010-10-12 2017-03-07 Arizona Cancer Therapeutics, Llc EGFR-based peptides
US9671407B2 (en) 2009-03-24 2017-06-06 Biocept, Inc. Devices and methods of cell capture and analysis
US10066004B2 (en) 2010-10-12 2018-09-04 Arizona Cancer Therapeutics, Llc EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3
JP2019518934A (ja) * 2016-04-05 2019-07-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 単一細胞刺激摂動応答に基づく標的化療法のためのシステムおよび方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP2032719A2 (en) * 2006-06-02 2009-03-11 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
GB0720118D0 (en) * 2007-10-15 2007-11-28 Achour Adnane Modified mhc class 1 binding peptides
WO2009068621A1 (en) * 2007-11-30 2009-06-04 Glaxosmithkline Biologicals S.A. Method for classifying cancer patients as responder or non-responder to immunotherapy
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
PE20141114A1 (es) 2010-12-20 2014-09-15 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
US20150044224A1 (en) * 2012-03-02 2015-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Materials and methods for differential treatment of cancer
WO2014074785A1 (en) * 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
US20220370586A1 (en) * 2019-08-08 2022-11-24 Cedars-Sinai Medical Center Method of generating activated t cells for cancer therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
WO2002090986A1 (en) 2001-05-04 2002-11-14 Ludwig Institute For Cancer Research Colon cancer antigen panel
WO2003100432A2 (de) * 2002-05-29 2003-12-04 Immatics Biotechnologies Gmbh Verfahren zur identifizierung von immunreaktiven peptiden

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
WO2002090986A1 (en) 2001-05-04 2002-11-14 Ludwig Institute For Cancer Research Colon cancer antigen panel
WO2003100432A2 (de) * 2002-05-29 2003-12-04 Immatics Biotechnologies Gmbh Verfahren zur identifizierung von immunreaktiven peptiden

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
JPN5007009179; ＮＥＵＭＡＮＮ　ＥＬＥＮＡ: ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ５８　Ｎ１８, 19980915, Ｐ４０９０-４０９５ *
JPN5007009180; ＤＥ　ＶＲＩＥＳ　Ｔ　Ｊ: ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ５７, 19970801, Ｐ３２２３-３２２９, ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ
JPN5007009180; ＶＲＩＥＳ　ＤＥ　Ｔ　Ｊ: ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ５７, 19970801, Ｐ３２２３-３２２９, ＡＭＥＲＩＣＡＮ　ＡＳＳＯＣＩＡＴＩＯＮ　ＦＯＲ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ *
JPN5007009181; ＧＯＬＤ　Ｄ　Ｖ: ＪＯＵＲＮＡＬ　ＯＦ　ＴＨＥ　ＮＡＴＩＯＮＡＬ　ＣＡＮＣＥＲ　ＩＮＳＴＩＴＵＴＥ Ｖ７１　Ｎ１, 198307, Ｐ１１７-１２４ *
JPN5007009182; ＬＥＷＩＳ　Ｊ　Ｊ: ＳＥＭＩＮＡＲＳ　ＩＮ　ＣＡＮＣＥＲ　ＢＩＯＬＯＧＹ Ｖ６, 199512, Ｐ３２１-３２７, ＳＡＵＮＤＥＲＳ　ＳＣＩＥＮＴＩＦＩＣ　ＰＵＢＬＩＣＡＴＩＯＮＳ *
JPN5007009183; ＳＣＡＮＬＡＮ　Ｍ　Ｊ: ＢＲＥＡＳＴ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ３　Ｎ２, 2001, Ｐ９５-９８ *
JPN6011012391; ＭＡＳＨＩＮＯ，　Ｋ．，　ｅｔ　ａｌ．: 'Ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ｍｕｌｔｉｐｌｅ　ｃａｎｃｅｒ-ｔｅｓｔｉｓ　ａｎｔｉｇｅｎ　ｇｅｎｅｓ　ｉｎ　ｇａｓｔｒｏｉｎｔｅｓｔｉｎａｌ　ａｎｄ　ｂｒｅａｓｔ　ｃａｒｃｉｎｏｍａｓ' Ｂｒｉｔｉｓｈ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃａｎｃｅｒ Ｖｏｌ．８５，　Ｎｏ．５, 2001, ｐ．７１３-７２０ *
JPN6011012394; ＭＡＥＵＲＥＲ，　Ｍ．Ｊ．，　ｅｔ　ａｌ．: 'Ｎｅｗ　ｔｒｅａｔｍｅｎｔ　ｏｐｔｉｏｎｓ　ｆｏｒ　ｐａｔｉｅｎｔｓ　ｗｉｔｈ　ｍｅｌａｎｏｍａ：　ｒｅｖｉｅｗ　ｏｆ　ｍｅｌａｎｏｍａ-ｄｅｒｉｖｅｄ　Ｔ-ｃｅｌｌ　ｅｐｉｔｏｐｅ-ｂａｓｅｄ　ｐｅ' Ｍｅｌａｎｏｍａ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．６, 1996, ｐ．１１-２４ *
JPN6011012396; 小幡裕一，　他．: Ｂｉｏｔｈｅｒａｐｙ Ｖｏｌ．１３，　Ｎｏ．１０, 199910, ｐ．１０２１-１０３０ *
JPN6011012398; ＫＡＷＡＫＡＭＩ，　Ｙ．，　ｅｔ　ａｌ．: 'Ｒｅｃｏｇｎｉｔｉｏｎ　ｏｆ　Ｓｈａｒｅｄ　Ｍｅｌａｎｏｍａ　Ａｎｔｉｇｅｎｓ　ｉｎ　Ａｓｓｏｃｉａｔｉｏｎ　Ｗｉｔｈ　Ｍａｊｏｒ　ＨＬＡ-Ａ　Ａｌｌｅｌｅｓ　ｂｙ　Ｔｕｍｏｒ　Ｉｎｆｉｌｔｒａｔｉｎ' Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｔｈｅｒａｐｙ Ｖｏｌ．２３，　Ｎｏ．１, 2000, ｐ．１７-２７ *
JPN6011012400; ＴＡＫＥＵＣＨＩ，　Ｈ．，　ｅｔ　ａｌ．: ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖｏｌ．６３, 20030115, ｐ．４４１-４４８ *
JPN6011012402; ＳＡＲＤＩ，　Ｉ．，　ｅｔ　ａｌ．: ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＪＯＵＲＮＡＬ　ＯＦ　ＭＯＬＥＣＵＬＡＲ　ＭＥＤＩＣＩＮＥ Ｖｏｌ．３, 1999, ｐ．４１７-４１９ *
JPN6014035737; Ｒａｍｍｅｎｓｅｅ　ＨＧ　ｅｔ　ａｌ．: 'Ｔｏｗａｒｄｓ　ｐａｔｉｅｎｔ-ｓｐｅｃｉｆｉｃ　ｔｕｍｏｒ　ａｎｔｉｇｅｎ　ｓｅｌｅｃｔｉｏｎ　ｆｏｒ　ｖａｃｃｉｎａｔｉｏｎ．' Ｉｍｍｕｎｏｌ　Ｒｅｖ． １８８, 200210, １６４-７６
JPN7013000643; ＳＡＨＩＮ，　Ｕ．　ｅｔ　ａｌ: 'Ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ｃａｎｃｅｒ　ｔｅｓｔｉｓ　ｇｅｎｅｓ　ｉｎ　ｈｕｍａｎ　ｂｒａｉｎ　ｔｕｍｏｒｓ' Ｃｌｉｎ　Ｃａｎｃｅｒ　Ｒｅｓ Ｖｏｌ．６，　Ｎｏ．１０, 2000, ｐ．３９１６-２２
JPN7013000644; ＳＣＡＮＬＡＮ，　Ｍ．　Ｊ．　ｅｔ　ａｌ: 'Ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ｃａｎｃｅｒ-ｔｅｓｔｉｓ　ａｎｔｉｇｅｎｓ　ｉｎ　ｌｕｎｇ　ｃａｎｃｅｒ：　ｄｅｆｉｎｉｔｉｏｎ　ｏｆ　ｂｒｏｍｏｄｏｍａｉｎ　ｔｅｓｔｉｓ-ｓｐｅｃｉｆｉｃ　ｇｅｎｅ' Ｃａｎｃｅｒ　Ｌｅｔｔ Ｖｏｌ．１５０，　Ｎｏ．２, 2000, ｐ．１５５-６４
JPN7013000646; ＴＡＪＩＭＡ，　Ｋ．　ｅｔ　ａｌ: 'Ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ｃａｎｃｅｒ／ｔｅｓｔｉｓ　（ＣＴ）　ａｎｔｉｇｅｎｓ　ｉｎ　ｌｕｎｇ　ｃａｎｃｅｒ' Ｌｕｎｇ　Ｃａｎｃｅｒ Ｖｏｌ．４２，　Ｎｏ．１, 2003, ｐ．２３-３３
JPN7013000649; ＯＤＵＮＳＩ，　Ｋ．　ｅｔ　ａｌ: 'ＮＹ-ＥＳＯ-１　ａｎｄ　ＬＡＧＥ-１　ｃａｎｃｅｒ-ｔｅｓｔｉｓ　ａｎｔｉｇｅｎｓ　ａｒｅ　ｐｏｔｅｎｔｉａｌ　ｔａｒｇｅｔｓ　ｆｏｒ　ｉｍｍｕｎｏｔｈｅｒａｐｙ　ｉｎ　ｅｐｉｔｈｅｌｉａｌ　ｏｖａ' Ｃａｎｃｅｒ　Ｒｅｓ． ｖＯＬ．６３，　Ｎｏ．１８, 2003, ｐ．６０７６-８３

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512415A (ja) * 2008-02-20 2011-04-21 アリゾナ バイオメディカル リサーチ コミッション 癌の治療および予防のための治療用ペプチドの使用
JP2015028034A (ja) * 2008-02-20 2015-02-12 アリゾナ キャンサー セラピューティクス リミテッド ライアビリティカンパニー 癌の治療および予防のための治療用ペプチドの使用
JP2012512389A (ja) * 2008-12-15 2012-05-31 オックスフォード バイオメディカ （ユーケー） リミテッド 方法
JP2012522217A (ja) * 2009-03-24 2012-09-20 バイオセプト インコーポレイティッド 細胞の捕捉および解析のデバイスおよび方法
US9128082B2 (en) 2009-03-24 2015-09-08 Biocept, Inc. Devices and methods of cell capture and analysis
US9671407B2 (en) 2009-03-24 2017-06-06 Biocept, Inc. Devices and methods of cell capture and analysis
US10527611B2 (en) 2009-03-24 2020-01-07 Biocept, Inc. Devices and methods of cell capture and analysis
US11719692B2 (en) 2009-03-24 2023-08-08 Biocept, Inc. Devices and methods of cell capture and analysis
US9585938B2 (en) 2010-10-12 2017-03-07 Arizona Cancer Therapeutics, Llc EGFR-based peptides
US10066004B2 (en) 2010-10-12 2018-09-04 Arizona Cancer Therapeutics, Llc EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3
JP2019518934A (ja) * 2016-04-05 2019-07-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 単一細胞刺激摂動応答に基づく標的化療法のためのシステムおよび方法

Also Published As

Publication number Publication date
AU2005258014B2 (en) 2012-07-12
EP1782070A2 (en) 2007-05-09
WO2006002114A2 (en) 2006-01-05
MXPA06014771A (es) 2007-03-21
ATE480776T1 (de) 2010-09-15
WO2006002114A3 (en) 2006-10-05
ES2351995T3 (es) 2011-02-14
DK1782070T3 (da) 2011-01-03
AU2005258014A1 (en) 2006-01-05
DE602005023488D1 (de) 2010-10-21
EP1782070B1 (en) 2010-09-08
CA2571070A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
US20120258462A1 (en) Combinations of tumor-associated antigens in diagnostics for various types of cancers
JP2008503498A (ja) 癌の診断及び免疫療法における腫瘍関連抗原プロファイル
JP5283335B2 (ja) 各種癌の治療を目的とした腫瘍関連抗原の組合せ
AU2005321898B2 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US20060159689A1 (en) Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20110274723A1 (en) Cancer immunotherapy and method of treatment
KR20190034504A (ko) 네오에피토프 백신 조성물 및 이의 사용 방법
JPH10505481A (ja) メラノーマ抗原
EA019603B1 (ru) Новые и действенные пептиды мнс ii класса, полученные из сурвивина
JP2019512020A (ja) がんの治療
Han et al. Adoptive T-cell transfer to treat lymphangioleiomyomatosis
Gerard et al. A comprehensive preclinical model evaluating the recombinant PRAME antigen combined with the AS15 immunostimulant to fight against PRAME-expressing tumors
CN101171032A (zh) 天然肽及其优化的衍生物作为疫苗的应用
JP2003502273A (ja) 正常な前立腺、精巣、および子宮ならびに新生物性の前立腺、精巣、および子宮に発現されたｘ連鎖ｇａｇｅ様遺伝子であるｐａｇｅ−４、ならびにその使用
Lollini et al. Preclinical vaccines against mammary carcinoma
JP2003527826A (ja) 癌関連抗原およびその使用
Slovin Prostate-specific membrane antigen vaccines: naked DNA and protein approaches
JP2003500072A (ja) 癌関連薬剤およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120404

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120620

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130131

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130222